Drug Trial Radar · NCT04246047
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
494
Actual
Start
May 7, 2020
Primary completion
Oct 2, 2023
Study completion Oct 8, 2029
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
Conditions
- Multiple Myeloma
Interventions
Belantamab mafodotinDrug
Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate
DaratumumabDrug
Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody
BortezomibDrug
Proteasome Inhibitor
DexamethasoneDrug
Synthetic glucocorticoid with anti-tumor activity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Up to approximately 41 months
Locations
143 sites in 20 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Yuma, Arizona
GSK Investigational Site
Mission, Kansas
GSK Investigational Site
Denver, North Carolina
GSK Investigational Site
Blue Ash, Ohio
GSK Investigational Site
Tyler, Texas
GSK Investigational Site
Roanoke, Virginia
GSK Investigational Site
Camperdown, New South Wales, Australia
GSK Investigational Site
Liverpool, New South Wales, Australia
GSK Investigational Site
Newcastle, New South Wales, Australia
GSK Investigational Site
St Leonards, New South Wales, Australia
GSK Investigational Site
Wollongong, New South Wales, Australia
GSK Investigational Site
Benowa, Queensland, Australia
GSK Investigational Site
Herston, Queensland, Australia
GSK Investigational Site
Ashford, South Australia, Australia
GSK Investigational Site
Box Hill, Victoria, Australia
GSK Investigational Site
Heidelberg, Victoria, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
Murdoch, Western Australia, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Roeselare, Belgium
GSK Investigational Site
Jette, Brussels Capital, Belgium
GSK Investigational Site
Woluwé-Saint-Lambert, Brussels Capital, Belgium
GSK Investigational Site
Ghent, Oost-Vlaanderen, Belgium
GSK Investigational Site
Joinville, Brazil
GSK Investigational Site
Natal, Brazil
GSK Investigational Site
Rio de Janeiro, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Florianópolis, Santa Catarina, Brazil
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Changchun, China
GSK Investigational Site
Guangzhou, China
GSK Investigational Site
Guangzhou, China
GSK Investigational Site
Hangzhou, China
Showing 40 of 143 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.